English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

The role of IL-10 (Interleukin 10) in the patients with SIRS was demonstrated in relation to the TNF (Tumor Necrosis Factor). 1. Clinical observations Thirty three materials of IL-10 and 43 materials of TNF were taken from a total of 46 patients with SIRS. And their concentration of serum were compared with those of healthy volunteers (TNF: n = 12, IL-10: n = 9). The value of IL-10 and TNF in SIRS patients was significantly higher than those of healthy volunteers (p &gt; 0.05 in IL-10, p &lt; 0.01 in TNF). Also, the values of both IL-10 and TNF in the patients with MOF (n = 22) were higher than those of the patients without MOF (n = 24) (p &lt; 0.05 in IL-10, p &lt; 0.01 in TNF). Both the serum values of IL-10 and TNF in 7 patients with SIRS, whose materials were obtained at two points of their clinical course, were decreased in accordance with the favorable prognosis. In these patients, the changes in IL-10 and TNF were observed in parallel. 2. Experimental observations Five 4 week ICR mice were used in an experimental study. The serum concentration of TNF and IL-10 increased to the maximum at 2 hours after 4 mg/kg of LPS injection. TNF level disappeared at 6 hours, but IL-10 level still remained at this point. Both the serum and BALF levels of TNF increased by LPS injection which was inhibited by the intraabdominal pretreatment of 200 micrograms of IL-10 (in serum: p &lt; 0.1, in BALF: p &lt; 0.05). By preincubation of mice alveolar macrophages with IL-10, TNF production from the macrophage resulting from LPS loading also was significantly inhibited (p &lt; 0.01). 3. From the above, it may be concluded that IL-10 inhibits TNF secretion from monocyte and protects against the pathogenic activity of TNF in the SIRS patient.

The Role of IL-10 in Patients with SIRS (Systemic Inflammatory Response Syndrome)